Table 3.

Gene co-expression analysis of protein–protein interactions.

Tumors	Protein–Protein Interactions
DLBC	MVK **—GSS (L—L) ***, MVK—ENO1 (L—M), MVD—EIF4EBP1 (L—M), SQLE—FAF2 (M—L), SQLE—TMCO3 (M—n/d), LSS—MYO5C (M—n/d), CYP51A1—ETS1 (n/d—H), MSMO1—C3AR1 (n/d—n/d), MSMO1—ELAVL1 (n/d—M, MSMO1—P2RX5 (n/d—M), EBP—VKORC1 (n/d—n/d), EBP—ENO1 (n/d—M)
PAAD	MSMO1—GPR35(n/d—n/d), EBP—MOV10 (L—n/d), DHCR7—FADS1 (H—M)
PRAD	DHCR24—ERAP1(n/d—M), DHCR24—CKAP5 (n/d—M), DHCR24—PTPN1 (n/d—n/d), DHCR24—REEP5 (n/d—M), DHCR24—UBL4A (n/d—M)
READ	HMGCR—VCP (M—M), DHCR24—CKAP5 (M—M), HMGCR—INSIG1 (M—n/d), DHCR7—FADS1 (H—M)
THYM	MVK—TACC3, FDPS—ATXN1, FDPS—PSME4, FDPS—TALDO1, FDPS—SEC31A, SQLE—MARCH6, SQLE—CHRND, LSS—ALOX5, LSS—MYH9, CYP51A1—SPINT2, MSMO1—ATXN1, MSMO1—ELAVL1, HSD17B7—GORAB, SC5D—IPPK, EBP—HSP90B1 (neg *), EBP—ABCE1 (neg), EBP—KSR1 (neg), EBP—TCTN2 (neg), EBP—BSCL2 (neg), EBP—MFSD8 (neg), FDPS—NME1, SQLE—FAF2, SQLE—TMCO3, MSMO1—EIF3A, EBP—NCSTN (neg)

Abbreviations: DLBC—lymphoid neoplasm diffuse large B-cell lymphoma; PAAD—pancreatic adenocarcinoma; PRAD—prostate adenocarcinoma; READ—rectum adenocarcinoma; THYM—thymoma. * Negative correlation. ** Cholesterol synthesis enzymes are underlined. *** Prevalent protein expression (according to Human Proteome Atlas): H—high; M—medium; L—low; n/d—no data.